Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news